Five Reasons Leading CNS Programs Rely on BrainXell for Custom iPSC Models
Scientist
on
February 25, 2026
This blog post was written by BrainXell. An industry-leading producer of neurons and glia advancing neuroscience research and partnering with over 75% of the world’s leading pharmaceutical companies, BrainXell works to develop products, services and applications using proprietary technology to guide human stem cells, including induced pluripotent stem cells (iPSCs), into highly enriched specialized neurons. Their services are available on Scientist.com.
1. Custom iPSC Differentiation Designed Around Biological Relevance
BrainXell specializes in custom human iPSC differentiation programs tailored to specific neuronal and glial phenotypes, developmental stages and experimental endpoints. They partner with over 75% of the world’s largest pharmaceutical companies to deliver high quality neurons and glia. In addition to ready-to-purchase off-the-shelf production, BrainXell works with their clients to define lineage specification, maturation state and functional characteristics aligned with disease biology, target expression or circuit-level questions. This approach enables more predictive human CNS models for discovery, translational research and therapeutic development.
2. Scalable, Controlled Cell Production for Discovery Through Translation
BrainXell supports custom and expanded production scales, ranging from small pilot batches to large-scale manufacturing of tens of millions to billions of cells. Production workflows are designed to maintain consistency across batches while accommodating project-specific needs such as staggered deliveries, cryopreservation formats or assay-ready plating. This scalability allows clients to use a single biological system across early discovery, screening and advanced validation, reducing variability introduced by changing models mid-program.
3. End-to-End Expertise Across Cell Line Selection, QC and Delivery
Custom projects are supported by scientific input at every stage, from iPSC line selection and feasibility assessment to differentiation optimization, quality control and final delivery. BrainXell performs rigorous characterization using molecular, phenotypic and functional readouts to ensure that cells meet predefined criteria before release. This integrated oversight minimizes technical risk and ensures that experimental data reflect true biology rather than production artifacts.
4. Integrated Functional and Molecular Assay Services
BrainXell extends beyond cell production by offering assay services tightly coupled to the underlying biology. Clients can pair custom cells with assays such as viability and cytotoxicity testing, gene expression analysis (qPCR), immunofluorescence imaging and electrophysiological measurements using multi-electrode array (MEA) platforms. These assays enable direct validation of cell identity, maturity and functional activity, providing richer datasets and accelerating go/no-go decisions.
5. A Unified Platform for Human-Relevant, Translational CNS Data
By combining custom iPSC differentiation, scalable production and integrated assays, BrainXell delivers a unified platform for generating human-relevant CNS data. This reduces the need to coordinate across multiple vendors and ensures biological continuity from cell generation through functional testing. The result is greater reproducibility, improved translational confidence and faster progression from mechanistic insight to actionable outcomes.
Learn more at brainxell.com.